Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment
N. Cantoni,M. Heizmann,M. Bargetzi
DOI: https://doi.org/10.1111/j.1365-2141.2012.09051.x
2012-06-01
British Journal of Haematology
Abstract:Boue, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., Billaud, E., Raphael, M., Lancar, R. & Costagliola, D. (2006) Phase II trial of CHOP plus rituximab in patients with HIVassociated non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 24, 4123–4128. Bower, M., Gazzard, B., Mandalia, S., NewsomDavis, T., Thirlwell, C., Dhillon, T., Young, A. M., Powles, T., Gaya, A., Nelson, M. & Stebbing, J. (2005) A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy. Annals of Internal Medicine, 143, 265–273. Crum-Cianflone, N., Hullsiek, K.H., Marconi, V., Weintrob, A., Ganesan, A., Barthel, R.V., Fraser, S., Agan, B.K. & Wegner, S. (2009) Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS, 23, 41–50. Kaplan, L.D., Lee, J.Y., Ambinder, R.F., Sparano, J. A., Cesarman, E., Chadburnm, A., Levine, A.M. & Scadden, D.T. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 106, 1538–1543. Navarro, J.T., Lloveras, N., Ribera, J.M., Oriol, A., Mate, J.L. & Feliu, E. (2005) The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica, 90, 704–706. Patel, P., Hanson, D.L., Sullivan, P.S., Novak, R. M., Moorman, A.C., Tong, T.C., Holmberg, S. D. & Brooks, J.T. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Annals of Internal Medicine, 148, 728–736. Ribera, J.M., Oriol, A., Morgades, M., GonzálezBarca, E., Miralles, P., López-Guillermo, A., Gardella, S., López, A., Abella, E. & Garcı́a, M. (2008) Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. British Journal of Haematology, 140, 411–419. Sparano, J.A., Lee, J.Y., Kaplan, L.D., Levine, A.M., Ramos, J.C., Ambinder, R.F., Wachsman, W., Aboulafia, D., Noy, A., Henry, D.H., von Roenn, J., Dezube, B.J., Remick, S.C., Shah, M.H., Leichman, L., Ratner, L., Cesarman, E., Chadburn, A. & Mitsuyasu, R. (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood, 115, 3008– 3016. Spina, M., Jaeger, U., Sparano, J.A., Talamini, R., Simonelli, C., Michieli, M., Rossi, G., Nigra, E., Berretta, M., Cattaneo, C., Rieger, A.C., Vaccher, E. & Tirelli, U. (2005) Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood, 105, 1891–1897. Wyen, C., Jensen, B., Hentrich, M., Siehl, J., Sabranski, M., Esser, S., Gillor, D., Müller, M., van Lunzen, J., Wolf, T., Bogner, J.R., Wasmuth, J. C., Christ, H., Fätkenheuer, G. & Hoffmann, C. (2011) Treatment of AIDS-related Lymphomas (ARL): rituximab is beneficial even in severely immunosuppressed patients. AIDS, Nov 22 E-pub ahead of print.